ResearchAndMarkets.com has added reports assessing bone neoplasms and chondrosarcoma across the seven major markets through 2036. The broader bone-neoplasms report covers primary and metastatic disease, epidemiology from 2022 to 2036, diagnosis, treatment, market size, therapy uptake, competitive dynamics, reimbursement and unmet needs. Its chondrosarcoma analysis forecasts approximately 16% annual market growth from 2026 to 2036, with the seven-market business valued at about $15 million in 2025 and the United States accounting for roughly $10 million. Approximately 2,300 chondrosarcoma cases were recorded across the seven markets in 2025, with conventional disease representing about 80% of cases and IDH mutations present in approximately 50% to 70% of tumors. Surgery remains the primary curative treatment for localized chondrosarcoma, while conventional disease has limited sensitivity to chemotherapy and radiotherapy and no drug is specifically approved for chondrosarcoma. The reports identify marketed mifamurtide and pipeline candidates including risvutatug rezetecan, GSK5764227, HS-20093, Servier's ivosidenib and Inhibrx's INBRX-109, also known as ozekibart. Growth prospects depend on improved imaging, molecular diagnostics, biomarker-defined treatment, targeted therapies and multidisciplinary care, while substantial unmet needs remain in advanced, recurrent, metastatic and treatment-resistant disease.